FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362595704> ?p ?o ?g. }

• W4362595704 endingPage "3358" @default.
• W4362595704 startingPage "3358" @default.
• W4362595704 abstract "Abstract Introduction: Surgery followed by adjuvant chemotherapy (ACT) is standard of care in stage III colon cancer. However, 50% of the patients would be cured by surgery alone and are being overtreated, while 30-35% will experience a recurrence despite adjuvant treatment, resulting in only 15-20% of the patients benefitting from ACT. Therefore, there is a need for prognostic biomarkers to better stratify this group of patients for ACT decisions. Recent observational and interventional studies in non-metastatic colon cancer have shown that detection of cell-free circulating tumor DNA (ctDNA) in blood after surgery is highly prognostic for development of recurrence. Hence, ctDNA analysis is a promising approach to guide treatment decisions in stage III colon cancer, but studies with large well-defined patient cohorts are needed to prove clinical utility. Aim: Determine the prognostic value of ctDNA in stage III colon cancer patients treated with ACT to reduce futile treatment. Methods: 241 stage III colon cancer patients treated with ACT were included in the prospective observational study “PROVENC3” (PROgnostic Value of Early Notification by Ctdna in Colon Cancer stage 3), a substudy of the Prospective Dutch Colorectal Cancer cohort (PLCRC). The PLCRC infrastructure accrued patients with colorectal cancer in 23 participating hospitals in the Netherlands. After informed consent, blood was collected pre-surgery, post-surgery, post-ACT and every six months up to 3 years. Tumor-informed detection of ctDNA was performed through integrated whole genome sequencing (WGS) analyses of formalin-fixed paraffin-embedded tumor tissue DNA (80x), germline DNA (40x), and plasma cell-free DNA (30x). Results: Patient accrual was completed in 2021, with a median follow-up of 35.6 months. In total, 1090 blood samples have been collected to date. Analytical studies demonstrated a limit of detection of the test of 0.005% ctDNA utilizing contrived reference models derived from six independent cell lines, with a specificity of 99.6% across 119 noncancerous donor plasma specimens. From the PROVENC3 study, ctDNA analyses are ongoing for pre-surgery (n=68) and post-surgery (n=241 patients) blood samples. Preliminary results demonstrated a ctDNA detection rate of 93.4% pre-surgery and 17.1% post-surgery, which was associated with disease recurrence. Final analysis will enable determination of: 1) the proportion of ctDNA-positive/negative patients after surgery and the corresponding recurrence rates; 2) the prognostic value of post-surgery ctDNA; and 3) the lead time between post-surgery ctDNA detection and recurrence. Future Perspective: Ultimately, the results of this study will be used to model and design a ctDNA-guided interventional trial in stage III colon cancer patients, to reduce futile ACT and its associated side-effects. Citation Format: Carmen Rubio-Alarcon, Steven L. Ketelaars, Ingrid A. Franken, Sietske C. van Nassau, Dave E. van der Kruijssen, Suzanna J. Schraa, Theodora C. Linders, Pien Delis-van Diemen, Maartje Alkemade, Anne Bolijn, Marianne Tijssen, Margriet Lemmens, Miranda van Dongen, Mirthe Lanfermeijer, Annegien Broeks, Lana Meiqari, Linda J. Bosch, Victor E. Velculescu, Amy Greer, Samuel V. Angiuoli, Andrew Georgiadis, David Riley, James R. White, Christopher Greco, Liam Cox, Daan van den Broek, Cornelis J. Punt, Veerle M. Coupé, Miriam Koopman, Jeanine Roodhart, Gerrit A. Meijer, Mark Sausen, Geraldine R. Vink, Remond J. Fijneman. PLCRC-PROVENC3: assessing the prognostic value of post-surgery liquid biopsy cell-free circulating tumor DNA in stage III colon cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3358." @default.
• W4362595704 created "2023-04-06" @default.
• W4362595704 creator A5001114958 @default.
• W4362595704 creator A5001408657 @default.
• W4362595704 creator A5001785282 @default.
• W4362595704 creator A5006560755 @default.
• W4362595704 creator A5017533272 @default.
• W4362595704 creator A5022147019 @default.
• W4362595704 creator A5027272901 @default.
• W4362595704 creator A5028581150 @default.
• W4362595704 creator A5034412439 @default.
• W4362595704 creator A5035727283 @default.
• W4362595704 creator A5035982396 @default.
• W4362595704 creator A5040500956 @default.
• W4362595704 creator A5041216249 @default.
• W4362595704 creator A5042679671 @default.
• W4362595704 creator A5043942519 @default.
• W4362595704 creator A5048216930 @default.
• W4362595704 creator A5049451329 @default.
• W4362595704 creator A5050300249 @default.
• W4362595704 creator A5053505290 @default.
• W4362595704 creator A5053630554 @default.
• W4362595704 creator A5057138806 @default.
• W4362595704 creator A5060815073 @default.
• W4362595704 creator A5061172196 @default.
• W4362595704 creator A5062928371 @default.
• W4362595704 creator A5070568270 @default.
• W4362595704 creator A5070586913 @default.
• W4362595704 creator A5075677040 @default.
• W4362595704 creator A5076310875 @default.
• W4362595704 creator A5077029853 @default.
• W4362595704 creator A5078199964 @default.
• W4362595704 creator A5078470750 @default.
• W4362595704 creator A5081322280 @default.
• W4362595704 creator A5081353089 @default.
• W4362595704 creator A5082794091 @default.
• W4362595704 date "2023-04-04" @default.
• W4362595704 modified "2023-10-02" @default.
• W4362595704 title "Abstract 3358: PLCRC-PROVENC3: assessing the prognostic value of post-surgery liquid biopsy cell-free circulating tumor DNA in stage III colon cancer patients" @default.
• W4362595704 doi "https://doi.org/10.1158/1538-7445.am2023-3358" @default.
• W4362595704 hasPublicationYear "2023" @default.
• W4362595704 type Work @default.
• W4362595704 citedByCount "0" @default.
• W4362595704 crossrefType "journal-article" @default.
• W4362595704 hasAuthorship W4362595704A5001114958 @default.
• W4362595704 hasAuthorship W4362595704A5001408657 @default.
• W4362595704 hasAuthorship W4362595704A5001785282 @default.
• W4362595704 hasAuthorship W4362595704A5006560755 @default.
• W4362595704 hasAuthorship W4362595704A5017533272 @default.
• W4362595704 hasAuthorship W4362595704A5022147019 @default.
• W4362595704 hasAuthorship W4362595704A5027272901 @default.
• W4362595704 hasAuthorship W4362595704A5028581150 @default.
• W4362595704 hasAuthorship W4362595704A5034412439 @default.
• W4362595704 hasAuthorship W4362595704A5035727283 @default.
• W4362595704 hasAuthorship W4362595704A5035982396 @default.
• W4362595704 hasAuthorship W4362595704A5040500956 @default.
• W4362595704 hasAuthorship W4362595704A5041216249 @default.
• W4362595704 hasAuthorship W4362595704A5042679671 @default.
• W4362595704 hasAuthorship W4362595704A5043942519 @default.
• W4362595704 hasAuthorship W4362595704A5048216930 @default.
• W4362595704 hasAuthorship W4362595704A5049451329 @default.
• W4362595704 hasAuthorship W4362595704A5050300249 @default.
• W4362595704 hasAuthorship W4362595704A5053505290 @default.
• W4362595704 hasAuthorship W4362595704A5053630554 @default.
• W4362595704 hasAuthorship W4362595704A5057138806 @default.
• W4362595704 hasAuthorship W4362595704A5060815073 @default.
• W4362595704 hasAuthorship W4362595704A5061172196 @default.
• W4362595704 hasAuthorship W4362595704A5062928371 @default.
• W4362595704 hasAuthorship W4362595704A5070568270 @default.
• W4362595704 hasAuthorship W4362595704A5070586913 @default.
• W4362595704 hasAuthorship W4362595704A5075677040 @default.
• W4362595704 hasAuthorship W4362595704A5076310875 @default.
• W4362595704 hasAuthorship W4362595704A5077029853 @default.
• W4362595704 hasAuthorship W4362595704A5078199964 @default.
• W4362595704 hasAuthorship W4362595704A5078470750 @default.
• W4362595704 hasAuthorship W4362595704A5081322280 @default.
• W4362595704 hasAuthorship W4362595704A5081353089 @default.
• W4362595704 hasAuthorship W4362595704A5082794091 @default.
• W4362595704 hasConcept C121608353 @default.
• W4362595704 hasConcept C126322002 @default.
• W4362595704 hasConcept C142724271 @default.
• W4362595704 hasConcept C143998085 @default.
• W4362595704 hasConcept C146357865 @default.
• W4362595704 hasConcept C151730666 @default.
• W4362595704 hasConcept C188816634 @default.
• W4362595704 hasConcept C204787440 @default.
• W4362595704 hasConcept C23131810 @default.
• W4362595704 hasConcept C2777863537 @default.
• W4362595704 hasConcept C2777982462 @default.
• W4362595704 hasConcept C2779529041 @default.
• W4362595704 hasConcept C526805850 @default.
• W4362595704 hasConcept C68122502 @default.
• W4362595704 hasConcept C71924100 @default.
• W4362595704 hasConcept C72563966 @default.
• W4362595704 hasConcept C86803240 @default.
• W4362595704 hasConceptScore W4362595704C121608353 @default.
• W4362595704 hasConceptScore W4362595704C126322002 @default.
• W4362595704 hasConceptScore W4362595704C142724271 @default.

• next